STOCK TITAN
  1. Home
  2. News
  3. EKSO

Ekso Bionics Holdings, Inc. - EKSO STOCK NEWS

Welcome to our dedicated page for Ekso Bionics Holdings news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics Holdings stock.

Ekso Bionics Holdings, Inc. (Symbol: EKSO) is a pioneering company in the field of robotic exoskeletons, or wearable robots, aimed at augmenting human strength, endurance, and mobility. Since its founding in 2005, Ekso Bionics has developed cutting-edge technology that has enabled thousands of people with paralysis to take millions of steps that would otherwise be impossible. Headquartered in Richmond, California, with international offices in London, the company has been a leader in both the healthcare and industrial markets.

Ekso Bionics operates through two main segments: EksoHealth and EksoWorks. The EksoHealth segment, which generates the majority of the company's revenue, focuses on designing, engineering, manufacturing, and selling exoskeletons for medical applications. These devices are worn over clothing and controlled by trained operators to assist individuals with mobility challenges. The EksoWorks segment, on the other hand, targets able-bodied users by creating exoskeleton devices that help them perform strenuous, repetitive tasks for extended periods.

Over the years, Ekso Bionics has been at the forefront of innovation, continuously pushing the boundaries of what robotic exoskeletons can achieve. Their products have not only redefined the scope of physical rehabilitation but have also found significant applications in various industrial settings, allowing workers to carry out challenging tasks more efficiently. Ekso Bionics is committed to breaking physical limitations and helping users reach new heights of capability.

For the latest updates, partnerships, and developments related to Ekso Bionics and their stock performance, visit StockTitan regularly.

News

Ekso Bionics Announces First Quarter 2024 Financial Results

Rhea-AI Summary

Ekso Bionics reported financial results for the first quarter of 2024, highlighting revenues of $3.8 million and a gross margin of 52%. The company achieved a final payment determination for Medicare reimbursement, sold 29 EksoHealth units, and focused on developing the market for Indego Personal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
earnings
-
News

Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024

Rhea-AI Summary
Ekso Bionics, a leader in exoskeleton technology for medical and industrial use, will report its first quarter 2024 financial results on April 29, 2024. The Company will discuss financial results and recent business developments in a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences earnings
-
News

Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal

Rhea-AI Summary
Ekso Bionics Holdings, Inc. announces Medicare reimbursement for Ekso Indego Personal at $91,031.93, effective April 1, 2024. The Healthcare Common Procedure Coding System Code K1007 approved for billing. Ekso Bionics to collaborate with clinics for patient qualification and training.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
News

Ekso Bionics Reports Record Annual Revenue of $18.3 Million

Rhea-AI Summary
Ekso Bionics Holdings, Inc. reported record revenue of $18.3 million in 2023, a 42% year-over-year increase. The Company sold 151 EksoHealth units and launched GaitCoach software. Despite a net loss of $15.2 million for the full year, Ekso remains optimistic about long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.76%
Tags
none
-
News

Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

Rhea-AI Summary
Ekso Bionics Holdings, Inc. (EKSO) will release financial and business results for Q4 and full year 2023 on March 4, 2024. The Company, known for exoskeleton technology, will host a conference call to discuss the results and recent developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences earnings
-
News

Ekso Bionics Announces $4.6 Million Registered Direct Offering

Rhea-AI Summary
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced a securities purchase agreement with institutional investors for the purchase and sale of 2,967,742 shares of common stock at a purchase price of $1.55 per share, resulting in total gross proceeds of approximately $4.6 million before deducting expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
offering
News

Ekso Bionics Launches GaitCoach Software for EksoNR

Rhea-AI Summary
Ekso Bionics Holdings, an industry leader in exoskeleton technology for medical and industrial use, announced the launch of GaitCoach™, its next generation gait therapy software for EksoNR. GaitCoach is designed to improve user trust in technology, provide impactful feedback, and offer specific guidance, making the device more intuitive and easier to use for both patients and physical therapists. The software has received positive feedback from experienced users, with 96% finding it intuitive and 93% believing it would be useful for new or less experienced therapists. However, the software is initially available only in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
none
-
News

Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2023. Total revenue for Q4 2023 is estimated to be in the range of $4.7 million to $4.9 million, compared to $3.6 million in Q4 2022. Total revenue for fiscal year 2023 is estimated to be in the range of $18.1 million to $18.3 million, compared to $12.9 million in 2022. Estimated cash as of December 31, 2023, was $8.6 million, compared to $20.5 million at December 31, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
earnings
-
News

Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal

Rhea-AI Summary
Ekso Bionics Holdings, an industry leader in exoskeleton technology for medical and industrial use, announced that the Centers for Medicare & Medicaid Services has approved the use of Healthcare Common Procedure Coding System Code K1007 for billing Medicare for their Ekso Indego Personal device. The proposed payment level is $94,617, expected to take effect on April 1, 2024. This milestone is expected to substantially lower the cost of the device for eligible individuals with spinal cord injuries, improving health outcomes and enhancing quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
News

Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29

Rhea-AI Summary
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced its participation at the CMS HCPCS public meeting to discuss Medicare payment for Ekso Indego Personal, aiming to provide thousands of individuals with spinal cord injuries access to their exoskeleton technology. The company submitted a coding verification request for reimbursement claims and expects a determination soon. The CMS' final rule published on November 1, 2023, will classify certain exoskeleton-type devices as braces for Medicare payment purposes, with any national payment amount established from the meeting effective April 1, 2024. Ekso Indego Personal is a modular, lightweight exoskeleton, offering advanced gait modes for increased walking speeds and independence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences

FAQ

What is the current stock price of Ekso Bionics Holdings (EKSO)?

The current stock price of Ekso Bionics Holdings (EKSO) is $0.5801 as of December 20, 2024.

What is the market cap of Ekso Bionics Holdings (EKSO)?

The market cap of Ekso Bionics Holdings (EKSO) is approximately 13.4M.

What does Ekso Bionics Holdings, Inc. do?

Ekso Bionics Holdings, Inc. designs, develops, and sells wearable robotic exoskeletons to augment human strength, endurance, and mobility.

Where is Ekso Bionics headquartered?

Ekso Bionics is headquartered in Richmond, California.

What are the main segments of Ekso Bionics?

Ekso Bionics operates through two main segments: EksoHealth and EksoWorks.

What does the EksoHealth segment specialize in?

The EksoHealth segment specializes in designing, engineering, manufacturing, and selling exoskeletons for medical applications.

What does the EksoWorks segment focus on?

The EksoWorks segment focuses on creating exoskeleton devices for able-bodied users to perform repetitive tasks more efficiently.

How has Ekso Bionics impacted people with paralysis?

Ekso Bionics' exoskeletons have helped thousands of people with paralysis take millions of steps that would otherwise be impossible.

In which regions does Ekso Bionics operate?

Ekso Bionics operates in the Americas, EMEA (Europe, Middle East, and Africa), and APAC (Asia-Pacific).

How can I get in touch with Ekso Bionics for investor relations?

For investor relations, you can contact David Carey at 212-867-1768 or via email at investors@eksobionics.com.

What innovations has Ekso Bionics brought to the industrial market?

Ekso Bionics has developed exoskeleton devices that enable workers to carry out difficult, repetitive tasks for extended periods, enhancing efficiency and reducing fatigue.

How does Ekso Bionics contribute to physical rehabilitation?

Ekso Bionics' exoskeletons are used in medical settings to assist individuals with mobility challenges, facilitating physical rehabilitation by aiding movement and strength.

Stock EKSO logo
Ekso Bionics Holdings, Inc.

Nasdaq:EKSO

EKSO Rankings

#5474 Ranked by Market Cap
N/A Ranked by Dividends

EKSO Stock Data

13.42M
20.03M
7.91%
25.25%
0.39%
Medical Instruments & Supplies
General Industrial Machinery & Equipment, Nec
Link
United States of America
SAN RAFAEL